
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is poised for long-term growth with its diverse portfolio of flagship drugs in the biotechnology field. Recently launched drugs like Repatha, Aimovig, Lumakras, and Tezspire are expected to drive strong revenue growth in the coming years. Additionally, Amgen's successful execution in external business development, such as the acquisition of Onyx Pharmaceuticals, could further enhance its expansion prospects. While there are potential risks such as product commercial and supply chain risks, Amgen's innovative therapies and strong market position make it a sound investment.
Bears say
Amgen is facing multiple downside risks including (1) disappointing pipeline data, particularly from MariTide and olpasiran; (2) potential erosion of current products such as Repatha and Otezla; and (3) regulatory and pricing risks that could decrease investor interest. Additionally, upcoming catalysts in 2027/2028, such as oncology and I&I pipeline assets, may not be sufficient to drive significant growth, and its total revenues are projected to remain in the range of $36B-$38B due to potential losses of exclusivity for key products like Prolia/Xgeva, Kyprolis, and Otezla. As a result, the financial analyst has a negative outlook on Amgen's stock.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares